Just a few days after scientists announced we're at a pivotal tipping point in Alzheimer's disease research, a team has made ...

In July 2025 following the close of 2Q 2025, Gain completed an underwritten public offering that resulted in approximately $7.1 million of net proceeds BETHESDA, Md., (GLOBE NEWSWIRE) -- Gain ...

The first-ever image of PINK1 proteins represents a groundbreaking moment in Parkinson’s disease research. This pivotal achievement promises to enhance our understanding of the disease’s mechanisms, ...

Cornell-led study reveals promising RNA biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), offering ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...